Clinical trials: H Pylori Infection
Helicobacter Pylori Infection
Community-based Helicobacter Pylori Eradication
Based on a universal eradication of H. pylori in an offshore island (Matsu) with a high prevalence of gastric cancer as well as premalignant gastric lesion, we first examined the infection rate of H. pylori.
- Trial name
- NCT00155389
- Testing
- Helicobacter pylori eradication
- Where
- 2 sites in Taiwan
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Abdominal Pain, Children
Resistance of Helicobacter Pylori to Antibiotics in Children
Helicobacter Pylori (HP) is one of the most common pathogens in humans. This infection can present in children with abdominal pain, vomiting and iron deficiency.
- Conditions
- Abdominal Pain, Children, Bacterial Infection Due to Helicobacter Pylori (H. Pylori), Antibiotic Resistant Strain
- Trial name
- NCT01902589
- Testing
- Helicobacter Pylori Culture
- Where
- Israel
- Volunteers
- 115 people
- Sponsor
- HaEmek Medical Center, Israel
Helicobacter Pylori Infection
Efficacy and Safety of 14-day Concomitant Therapy for Helicobacter Pylori Infection
The purpose of this study is to evaluate efficacy of a 14-day concomitant therapy for the third-line treatment of Helicobacter pylori infection, and whether it is safe while maintaining an ideal eradication rates.
- Trial name
- NCT04991584
- Testing
- Amoxicillin,Tetracycline,Furazolidone,Levofloxacin,Vonoprazan fumarate, Esomeprazole ,
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shandong University
Helicobacter Pylori Infection
Trimebutine on the Development of Adverse Events Related to the Helicobacter Pylori Eradication Medications
Adverse events related to the eradication medication is one of the reason of lower eradication success in the H. pylori treatment.
- Trial name
- NCT04403087
- Testing
- Trimebutine 100 MG
- Where
- South Korea
- Volunteers
- 132 people, healthy volunteers welcome
- Sponsor
- Chuncheon Sacred Heart Hospital
Helicobacter Pylori Infection
Clarithromycin Triple Therapy Plus Bismuth for Helicobacter Pylori First-line Treatment
Standard triple therapy including a proton pump inhibitor (PPI) and clarithromycin with either amoxicillin or metronidazole are no longer recommended as empirical first-line therapy to treat Helicobacter pylori infection because…
- Trial name
- NCT02732249
- Testing
- Esomeprazole, Bismuth Potassium Citrate, Clarithromycin
- Where
- China
- Volunteers
- 66 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Helicobacter Pylori Infection
Susceptibility Testing Guided Versus Empirical Therapy for Refractory H. Pylori Infection
Aim: Therefore, we aimed to 1. compare the efficacy of susceptibility testing guided therapy vs. empirical therapy in the third-line eradication for refractory H. pylori infection 2.
- Trial name
- NCT04332848
- Testing
- ET, SGT
- Where
- Taiwan
- Volunteers
- 360 people
- Sponsor
- National Taiwan University Hospital
Helicobacter Pylori Infection, Antimicrobial Susceptibility Testing
Antimicrobial Susceptibility Testing Guided Antibiotic Selection Strategies in Salvage Helicobacter Pylori Treatment
Helicobacter pylori (H. pylori), which infects about 50% of the global population, has been recognized as a main risk factor of multiple gastric pathologies, especially non-cardiac gastric cancer.
- Trial name
- NCT02988089
- Testing
- Clarithromycin susceptibility dependant strategy, 2 susceptible antibiotics (amoxicillin, clarithromycin, metronidazole, tinidazole,levofloxacin, furazolidone and tetracycline ), proton pump inhibitor (PPI) and Colloidal Bismuth Pectin
- Where
- China
- Volunteers
- 480 people
- Sponsor
- Shandong University
Helicobacter Pylori Infection
Telephone-Based Re-education for Hp Eradication
It was suggested that the patient compliance plans an important role in the Hp eradication. However, data on whether re-education could improve the eradication rate are lacking.
- Trial name
- NCT03193450
- Testing
- telephone-based re-education, First education at the clinic
- Where
- China
- Volunteers
- 162 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
H. Pylori Infection
A Comparative Study Between Concomitant Versus Load Therapy in Eradication of Helicobacter Pylori Infection
All patients who presented with epigastric pain and dyspeptic symptoms will undergo endoscopic gastric biopsies. The patients will be subjected to: Full history taking, clinical examination, liver function tests, renal function…
- Trial name
- NCT06050824
- Testing
- Comparing Load and Concomitant therapy
- Where
- Egypt
- Volunteers
- 200 people
- Sponsor
- Helwan University
Helicobacter Pylori Infection, Resistant Infection
One Sequencing Find All for Helicobacter Pylori Infection
The aim of this study is to Identify antibiotic resistance gene mutations in Helicobacter pylori (HP) and genetic diversity of drug metabolism for antibiotics and proton pump inhibitors (PPIs) in patients with HP infection using…
- Trial name
- NCT03837990
- Testing
- Helicobacter Pylori eradication therapy
- Where
- South Korea
- Volunteers
- 60 people
- Sponsor
- Seoul National University Hospital
Helicobacter Pylori Gastrointestinal Tract Infection
Comparison Efficacy of 14-day Triple Therapy: Clarithromycin vs. Levofloxacin on Eradication of H. Pylori
Comparison Efficacy of 14-day Triple Therapy between Clarithromycin and levofloxacin on the Eradication of Helicobacter Pylori in Syrian population
- Trial name
- NCT02693574
- Testing
- Clarithromycin, Levofloxacin
- Where
- Syria
- Volunteers
- 74 people
- Sponsor
- Damascus Hospital
Helicobacter Pylori Infection
Efficacy and Safety of Tegoprazan Versus Esomeprazole-containing Bismuth Quadruple Therapy for Eradication of Helicobacter Pylori
This study is a multicenter, randomized, double-blind, double-dummy, phase III study to evaluate the efficacy and safety of tegoprazan versus esomeprazole-containing bismuth quadruple therapy in patients infected with…
- Trial name
- NCT05577468
- Testing
- Tegoprazan
- Where
- China
- Volunteers
- 561 people
- Sponsor
- Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.
Helicobacter Pylori Infection
Efficacy and Safety of InSan Bamboo Salt on Improvement of Helicobacter Pylori Infection
The investigators performed a 4-week, randomized, double-blind, placebo-controlled human trial to evaluate the efficacy and safety of InSan Bamboo Salt on improvement of Helicobacter pylori infection.
- Trial name
- NCT01735136
- Testing
- InSan Bamboo Salt
- Where
- South Korea
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Chonbuk National University Hospital
HELICOBACTER PYLORI INFECTIONS
Comparison of the Efficacies of Two Novel Dose Dual Therapies in the First-line Helicobacter Pylori Eradication
Background: The key factors for success are the maintenance of intragastric pH > 6 and the drug resistance to antibiotics. Proton pump inhibitor (PPI)-based high-dose dual therapy is a novel anti-Helicobacter pylori (H.
- Trial name
- Helicobacter (NCT06811207)
- Testing
- Vonoprazan, Esomeprazole 40mg, Amoxicillin
- Where
- Taiwan
- Volunteers
- 300 people
- Sponsor
- Chang Gung Memorial Hospital
Helicobacter Pylori Infection
Efficacies of Susceptibility-guided vs Empiric Therapy for Rescue Treatment of Helicobacter Pylori Infection
The prevalence of H. pylori antibiotic resistance has reached an alarming level worldwide. Antibiotic stewardship programs should be urgently developed and implemented. However, H.
- Trial name
- NCT05332444
- Testing
- susceptibility-guided tailored therapy (Group A), guidelines-recommended empiric therapy (Group B)
- Where
- Taiwan
- Volunteers
- 450 people
- Sponsor
- National Taiwan University Hospital
Helicobacter Pylori Infection
Efficacies of Two Bismuth Quadruple Therapies in the Second-line Treatment of H Pylori Infection
From the profiles of antibiotic susceptibility data following eradication therapy, tetracycline, amoxicillin and levofloxacin are all good candidates of antibiotics used in the rescue treatment.
- Trial name
- NCT03779087
- Testing
- 10d TL quadruple therapy, 10d AL quadruple therapy
- Where
- Taiwan
- Volunteers
- 112 people
- Sponsor
- Ping-I (William) Hsu, M.D.
H. Pylori Infection
The Efficacy of Sequential Therapy as Second Line Therapy for Refractory Helicobacter Pylori Infection - A Pilot Study
Helicobacter pylori infection has been shown to be associated with the development of gastric cancer and peptic ulcer diseases. Eradication of H. pylori infection could reduce the occurence or recurrence of these diseases.
- Trial name
- NCT00885417
- Testing
- Cravit-based sequential therapy
- Where
- Taiwan
- Volunteers
- 142 people
- Sponsor
- National Taiwan University Hospital
Helicobacter Pylori Infection
Rescue Therapy for Helicobacter Pylori Eradication Treatment
Current guidelines have recommended classical bismuth-containing quadruple therapy including proton-pump inhibitor, bismuth, tetracycline, metronidazole as the empirical rescue therapy.
- Trial name
- NCT04531059
- Testing
- Esomeprazole, Bismuth Potassium Citrate, Tetracycline,Metronidazole
- Where
- 3 sites in China
- Volunteers
- 368 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Helicobacter Pylori Infection
Comparison of the Eradications Rates of Sequential Therapy Versus Concomitant Therapy
Comparison of the eradications rates of sequential therapy versus concomitant therapy of treatment of Helicobacter pylori infection in Korea. single center, randomized trial 1.
- Trial name
- NCT02108184
- Testing
- Sequential therapy 10 days, Sequential therapy 14 days, Concomitant therapy 10 days
- Where
- South Korea
- Volunteers
- 264 people, healthy volunteers welcome
- Sponsor
- Incheon St.Mary's Hospital
Helicobacter Pylori Infection
Efficacy and Safety Evaluation of Levofloxacin Triple Therapy for Helicobacter Pylori Eradication
Today, although the triple treatment with clarithromycin accepted as the primary treatment for Helicobacter pylori infection eradication is well tolerated, the eradication has been decreased to 65 %.
- Trial name
- NCT01131026
- Testing
- Levofloxacin, Amoxicillin, Lansoprazole
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people
- Sponsor
- Deva Holding A.S.